NEW YORK, August 11, 2017 /PRNewswire/ --
If you want a Stock Review on PCRX, EGRX, NEOS, or ZYNE then come overto http://dailystocktracker.com/register/ and sign up for your free customized report today. Today, DailyStockTracker.com takes note of the most recent performances of Pacira Pharmaceuticals Inc. (NASDAQ: PCRX), Eagle Pharmaceuticals Inc. (NASDAQ:
Parsippany, New Jersey headquartered Pacira Pharmaceuticals Inc.'s stock finished Thursday's session 1.23% lower at $36.20. A total volume of 800,623 shares was traded, which was above their three months average volume of 707,390 shares. The Company's shares have gained 12.07% since the start of this year. The stock is trading below its 200-day moving average by 13.76%. Moreover, shares of Pacira Pharma, which develops, manufactures, and commercializes proprietary pharmaceutical products primarily for use in hospitals and ambulatory surgery centers in the US, have a Relative Strength Index (RSI) of 24.02.
On August 09th, 2017, Pacira Pharma announced that members of its management team are scheduled to present at the 2017 Wedbush Pacgrow Healthcare Conference at 9:10 a.m. ET on August 15th, 2017, in New York City. The live audio webcast of the presentation can be accessed by visiting the "Investors & Media" section of the Company's website. Your complete research report on PCRX can be retrieved for free at:
Shares in Woodcliff Lake, New Jersey headquartered Eagle Pharmaceuticals Inc. rose 1.87%, ending yesterday's session at $50.07. A total volume of 618,359 shares was traded, which was above their three months average volume of 438,900 shares. The stock is trading 28.60% below its 50-day moving average. Moreover, shares of Eagle Pharma, which focuses on developing and commercializing injectable products primarily in the critical care and oncology areas in the US, have an RSI of 28.06.
On July 26th, 2017, Eagle Pharma announced that it has received a Complete Response Letter from the US Food and Drug Administration (FDA) regarding its 505(b)(2) New Drug Application for RYANODEX® (dantrolene sodium) for the treatment of exertional heat stroke (EHS), in conjunction with external cooling methods. In its letter, the FDA has requested that the Company to conduct an additional clinical trial for RYANODEX for EHS.
On July 27th, 2017, research firm RBC Capital Markets reiterated its 'Outperform' rating on the Company's stock with a decrease of the target price from $94 a share to $81 a share. A free report on EGRX is just a click away at:
On Thursday, Grand Prairie, Texas headquartered Neos Therapeutics Inc.'s stock climbed 2.92%, to close the day at $7.05. A total volume of 690,686 shares was traded, which was above their three months average volume of 626,830 shares. The Company's shares have advanced 6.82% in the last one month and 20.51% on an YTD basis. The stock is trading 2.67% above its 200-day moving average. Additionally, shares of Neos Therapeutics, which engages in the development, manufacture, and commercialization of products for the treatment of attention deficit hyperactivity disorder using its drug delivery technologies, have an RSI of 51.59.
On August 08th, 2017, Neos Therapeutics reported financial results for Q2 ended June 30th, 2017. Total product revenues for the quarter were $4.9 million, cost of goods sold was $2.6 million, gross profit was $2.3 million, and net loss was $18.7 million. At June 30th, 2017, the Company held $78.6 million in cash and cash equivalents and short-term investments.
On August 09th, 2017, research firm RBC Capital Markets reiterated its 'Outperform' rating on the Company's stock with a decrease of the target price from $20 a share to $12 a share. Sign up for your complimentary research report on NEOS at:
Shares in Devon, Pennsylvania headquartered Zynerba Pharmaceuticals Inc. ended the day 4.47% lower at $7.26. A total volume of 2.32 million shares was traded, which was above their three months average volume of 678,510 shares. The stock is trading below its 50-day moving average by 57.45%. Furthermore, shares of Zynerba Pharma, which focuses on developing and commercializing proprietary synthetic cannabinoid therapeutics formulated for transdermal delivery, have an RSI of 25.11.
On August 07th, 2017, Zynerba Pharma announced top-line results from its double-blind, placebo-controlled Phase-2 STAR 1 clinical trial evaluating ZYN002 (cannabidiol [CBD] gel) in adult epilepsy patients with focal seizures. ZYN002 did not demonstrate a statistically significant reduction of focal seizures during the treatment period compared to the baseline period for either the high- or low-dose cohorts compared to placebo. Register for free on DailyStockTracker.com and download the latest research report on ZYNE at:
Daily Stock Tracker:
Daily Stock Tracker (DST) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. DST has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
DST has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email firstname.lastname@example.org. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by DST. DST is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
DST, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. DST, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, DST, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither DST nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit
CONTACT For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at: Email: email@example.com Phone number: (207)331-3313 Office Address: 377 Rivonia Boulevard, Rivonia, South Africa
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Chelmsford Park SA
Subscribe to our Free Newsletters!
Inguinal hernia surgery is a procedure to repair a weak spot or defect in the lower wall of the ...
Hypopituitarism is a rare disorder resulting from decreased secretion of one or more of the ...
Palliative care is a specialized multifaceted care for patients with chronic or terminal illness to ...View All